Cover
Cover - shares | 6 Months Ended | |
Jun. 30, 2023 | Aug. 04, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Jun. 30, 2023 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2023 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 001-32146 | |
Entity Registrant Name | DSS, INC. | |
Entity Central Index Key | 0000771999 | |
Entity Tax Identification Number | 16-1229730 | |
Entity Incorporation, State or Country Code | NY | |
Entity Address, Address Line One | 275 Wiregrass Pkwy | |
Entity Address, City or Town | West Henrietta | |
Entity Address, State or Province | NY | |
Entity Address, Postal Zip Code | 14586 | |
City Area Code | (585) | |
Local Phone Number | 325-3610 | |
Title of 12(b) Security | Common Stock, $0.02 par value per share | |
Trading Symbol | DSS | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 140,264,250 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Jun. 30, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 10,033,000 | $ 19,290,000 |
Accounts receivable, net | 2,468,000 | 7,564,000 |
Inventory | 5,300,000 | 7,721,000 |
Assets held for sale | 1,524,000 | |
Current portion of notes receivable | 9,269,000 | 11,719,000 |
Prepaid expenses and other current assets | 1,199,000 | 1,700,000 |
Total current assets | 29,793,000 | 47,994,000 |
Property, plant and equipment, net | 12,438,000 | 13,391,000 |
Investment in real estate, net | 53,997,000 | 55,029,000 |
Other investments | 1,163,000 | 1,534,000 |
Investment, equity method | 139,000 | 162,000 |
Marketable securities | 11,575,000 | 27,307,000 |
Notes receivable | 1,112,000 | 922,000 |
Non-current assets held for sale | 480,000 | |
Other assets | 261,000 | 2,699,000 |
Right-of-use assets | 7,515,000 | 8,219,000 |
Goodwill | 57,880,000 | 60,919,000 |
Other intangible assets, net | 28,508,000 | 30,740,000 |
Total assets | 204,861,000 | 248,916,000 |
Current liabilities: | ||
Accounts payable | 3,046,000 | 5,914,000 |
Accrued expenses and deferred revenue | 3,080,000 | 19,341,000 |
Other current liabilities | 396,000 | 477,000 |
Current Liabilities held for sale | 1,129,000 | |
Current portion of lease liability | 633,000 | 796,000 |
Current portion of long-term debt, net | 47,206,000 | 47,161,000 |
Total current liabilities | 55,490,000 | 73,689,000 |
Long-term debt, net | 7,218,000 | 10,181,000 |
Long term lease liability | 7,120,000 | 7,820,000 |
Non-current liabilities held for sale | 59,000 | |
Other long-term liabilities | 507,000 | 507,000 |
Deferred tax liability | 38,000 | 38,000 |
Commitments and contingencies (Note 11) | ||
Stockholders’ equity | ||
Common stock, $.02 par value; 200,000,000 shares authorized, 140,264,250 shares issued and outstanding (139,017,172 on December 31, 2022) | 2,804,000 | 2,779,000 |
Additional paid-in capital | 317,369,000 | 317,126,000 |
Accumulated deficit | (221,529,000) | (194,343,000) |
Total stockholders’ equity | 98,644,000 | 125,562,000 |
Non-controlling interest in subsidiaries | 35,785,000 | 31,119,000 |
Total stockholders’ equity | 134,429,000 | 156,681,000 |
Total liabilities and stockholders’ equity | $ 204,861,000 | $ 248,916,000 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Jun. 30, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Common stock, par value | $ 0.02 | $ 0.02 |
Common stock, shares authorized | 200,000,000 | 200,000,000 |
Common stock, shares issued | 140,264,250 | 139,017,172 |
Common stock, shares outstanding | 140,264,250 | 139,017,172 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Revenue: | ||||
Total revenue | $ 7,233,000 | $ 11,771,000 | $ 19,064,000 | $ 24,064,000 |
Cost of revenue: | ||||
Printed Products | 2,421,000 | 2,603,000 | 7,081,000 | 6,026,000 |
Securities | 1,820,000 | 2,551,000 | 4,340,000 | 5,124,000 |
Biotechnology | 2,000 | 308,000 | 63,000 | 308,000 |
Direct Marketing | 516,000 | 1,990,000 | 1,806,000 | 4,127,000 |
Others | 73,000 | 218,000 | 75,000 | 700,000 |
Selling, general and administrative (including stock-based compensation) | 8,851,000 | 15,283,000 | 17,824,000 | 25,639,000 |
Total costs and expenses | 13,683,000 | 22,953,000 | 31,189,000 | 41,924,000 |
Operating loss | (6,450,000) | (11,182,000) | (12,125,000) | (17,860,000) |
Other income (expense): | ||||
Interest income | 407,000 | 139,000 | 538,000 | 295,000 |
Dividend income | 8,000 | 12,000 | ||
Other income (expense) | 147,000 | 2,344,000 | 175,000 | 576,000 |
Interest expense | (138,000) | (121,000) | (388,000) | (1,499,000) |
Gain on extinguishment of debt | 110,000 | 110,000 | ||
Loss on equity method investment | (18,000) | (99,000) | (22,000) | (211,000) |
(Loss)/gain on investments | (27,922,000) | 3,399,000 | (30,790,000) | 3,823,000 |
Provision for loan losses | (3,757,000) | (3,757,000) | ||
Gain on sale of assets | 405,000 | |||
Loss from continuing operations before income taxes | (37,723,000) | (5,410,000) | (46,357,000) | (14,361,000) |
Income tax benefit (loss) | ||||
Net loss | (37,723,000) | (5,410,000) | (46,357,000) | (14,361,000) |
(Income)/loss from continuing operations attributed to noncontrolling interest | (200,000) | 758,000 | 398,000 | 1,661,000 |
Net loss attributable to common stockholders | $ (37,923,000) | $ (4,652,000) | $ (45,959,000) | $ (12,700,000) |
Loss per common share: | ||||
Basic | $ (0.27) | $ (0.05) | $ (0.33) | $ (0.15) |
Diluted | $ (0.27) | $ (0.05) | $ (0.33) | $ (0.15) |
Shares used in computing loss per common share: | ||||
Basic | 140,140,913 | 34,888,054 | 139,579,043 | 85,641,957 |
Diluted | 140,140,913 | 34,888,054 | 139,579,043 | 85,641,957 |
Printed Products [Member] | ||||
Revenue: | ||||
Total revenue | $ 3,626,000 | $ 4,048,000 | $ 9,661,000 | $ 7,617,000 |
Rental Income [Member] | ||||
Revenue: | ||||
Total revenue | 1,543,000 | 1,508,000 | 3,228,000 | 3,171,000 |
Net Investment Income [Member] | ||||
Revenue: | ||||
Total revenue | 197,000 | 145,000 | 314,000 | 274,000 |
Direct Marketing [Member] | ||||
Revenue: | ||||
Total revenue | 1,572,000 | 6,070,000 | 5,566,000 | 13,002,000 |
Commission Revenue [Member] | ||||
Revenue: | ||||
Total revenue | $ 295,000 | $ 295,000 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Cash flows from operating activities: | |||||
Net loss from continuing operations | $ (46,357,000) | $ (14,361,000) | |||
Adjustments to reconcile net loss from continuing operations to net cash used by operating activities: | |||||
Depreciation and amortization | 2,647,000 | 6,425,000 | |||
Gain on allowance for obsolescence of inventory | (280,000) | ||||
Stock based compensation | 268,000 | 4,000 | |||
Income on equity method investment | 22,000 | 211,000 | |||
(Gain) loss on investments | 30,790,000 | (3,823,000) | |||
Change in ROU assets | 774,000 | (10,202,000) | |||
Change in ROU liabilities | (1,052,000) | 10,122,000 | |||
Gain on extinguishment of debt | $ (110,000) | (110,000) | |||
Gain on sale of assets | (405,000) | ||||
Impairment of notes receivable | 3,757,000 | 1,745,000 | |||
Decrease (increase) in assets: | |||||
Accounts receivable | 2,531,000 | (460,000) | |||
Inventory | 4,707,000 | 591,000 | |||
Prepaid expenses and other current assets | 592,000 | 1,307,000 | |||
Other assets | 3,123,000 | (312,000) | |||
Increase (decrease) in liabilities: | |||||
Accounts payable | (3,846,000) | 192,000 | |||
Accrued expenses | (15,958,000) | (3,036,000) | |||
Other liabilities | (81,000) | (373,000) | |||
Net cash used by operating activities - continuing operations | (18,083,000) | (13,947,000) | |||
Net cash used by operating activities - held for sale | (1,632,000) | ||||
Net cash used by operating activities | (19,715,000) | (13,947,000) | |||
Cash flows from investing activities: | |||||
Purchase of property, plant and equipment | (496,000) | (976,000) | |||
Purchase of real estate | (689,000) | ||||
Purchase of marketable securities | (4,805,000) | ||||
Disposal of property, plant and equipment | 215,000 | 2,557,000 | |||
Sale of marketable securities | 11,330,000 | ||||
Issuance of new notes receivable | (3,362,000) | ||||
Payments received on notes receivable | 2,327,000 | 863,000 | |||
Net cash provided by (used in) investing activities | 13,376,000 | (6,412,000) | |||
Cash flows from financing activities: | |||||
Payments of long-term debt | (5,519,000) | (169,000) | |||
Borrowings of long-term debt | 2,601,000 | 6,360,000 | |||
Deferred financing fees | |||||
Issuances of common stock, net of issuance costs | 1,518,000 | ||||
Net cash (used in) provided by financing activities | (2,918,000) | 7,709,000 | |||
Net increase (decrease) in cash - continuing operations | (7,625,000) | (12,650,000) | |||
Net increase (decrease) in cash – held for sale | (1,632,000) | ||||
Cash and cash equivalents at beginning of period | 19,290,000 | 56,595,000 | $ 56,595,000 | ||
Cash and cash equivalents at end of period | $ 10,033,000 | $ 43,945,000 | $ 10,033,000 | $ 43,945,000 | $ 19,290,000 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) | Common Stock [Member] | Preferred Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Parent [Member] | Noncontrolling Interest [Member] | Total |
Beginning balance, value at Dec. 31, 2021 | $ 1,594,000 | $ 294,685,000 | $ (134,503,000) | $ 161,776,000 | $ 36,409,000 | $ 198,185,000 | |
Beginning balance, shares at Dec. 31, 2021 | 79,746,000 | ||||||
Issuance of common stock, net of expenses | $ 80,000 | 1,438,000 | 1,518,000 | 1,518,000 | |||
Issuance of common stock, net of expenses, shares | 3,987,000 | ||||||
Net loss | (12,700,000) | (12,700,000) | (1,661,000) | (14,361,000) | |||
Stock based payments | $ 327,000 | 5,894,000 | 6,221,000 | 6,221,000 | |||
Stock based payments, shares | 16,347,000 | ||||||
Conversion of preferred stock | |||||||
Ending balance, value at Jun. 30, 2022 | $ 2,001,000 | 302,017,000 | (147,203,000) | 156,815,000 | 34,748,000 | 191,563,000 | |
Ending balance, shares at Jun. 30, 2022 | 100,080,000 | ||||||
Beginning balance, value at Dec. 31, 2022 | $ 2,779,000 | 317,126,000 | (194,343,000) | 125,562,000 | 31,119,000 | 156,681,000 | |
Beginning balance, shares at Dec. 31, 2022 | 139,017,000 | ||||||
Issuance of common stock, net of expenses | $ 25,000 | 243,000 | 268,000 | 268,000 | |||
Issuance of common stock, net of expenses, shares | 1,247,000 | ||||||
Deconsolidation of Sharing Services Global Corp | 18,773,000 | 18,773,000 | 5,064,000 | 23,837,000 | |||
Net loss | (45,959,000) | (45,959,000) | (398,000) | (46,357,000) | |||
Ending balance, value at Jun. 30, 2023 | $ 2,804,000 | $ 317,369,000 | $ (221,529,000) | $ 98,644,000 | $ 35,785,000 | $ 134,429,000 | |
Ending balance, shares at Jun. 30, 2023 | 140,264,000 |
Nature of Operations and Basis
Nature of Operations and Basis of Presentation and Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of Operations and Basis of Presentation and Significant Accounting Policies | 1. Nature of Operations and Basis of Presentation and Significant Accounting Policies The Company, incorporated in the state of New York in May 1984 has conducted business in the name of Document Security Systems, Inc. On September 16, 2021, the board of directors approved an agreement and plan of merger with a wholly owned subsidiary, DSS, Inc. (a New York corporation, incorporated in August 2020), for the sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This change became effective on September 30, 2021. DSS, Inc. maintained the same trading symbol “DSS” and updated its CUSIP number to 26253C 102. DSS, Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our” or the “Company”) currently operates nine (9) distinct business lines with operations and locations around the globe. These business lines are: (1) Product Packaging, (2) Biotechnology, (3) Direct Marketing, (4) Commercial Lending, (5) Securities and Investment Management, (6) Alternative Trading (7) Digital Transformation, (8) Secure Living, and (9) Alternative Energy. Each of these business lines are in different stages of development, growth, and income generation. Our divisions, their business lines, subsidiaries, and operating territories: (1) Our Product Packaging line is led by Premier Packaging Corporation, Inc. (“Premier”), a New York corporation. Premier operates in the paper board and fiber based folding carton, consumer product packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex 3-dimensional direct mail solutions. Premier is currently located in its new facility in Rochester, NY, and primarily serves the US market. (2) The Biotechnology business line was created to invest in or acquire companies in the BioHealth and BioMedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also targeting unmet, urgent medical needs, and is developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. (3) Direct Marketing, led by the holding corporation, Decentralized Sharing Systems, Inc. (“Decentralized”) provides services to assist companies in the emerging growth “Gig” business model of peer-to-peer decentralized sharing marketplaces. Direct specializes in marketing and distributing its products and services through its subsidiary and partner network, using the popular gig economic marketing strategy as a form of direct marketing. Direct Marketing’s products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific, Middle East, and Eastern Europe. (4) Our Commercial Lending business division, driven by American Pacific Bancorp (“APB”), is organized for the purposes of being a financial network holding company, focused on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting services, and advisory capital raising services. (5) Securities and Investment Management was established to develop and/or acquire assets in the securities trading or management arena, and to pursue, among other product and service lines, broker dealers, and mutual funds management. Also in this segment is the Company’s real estate investment trusts (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. The REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. (6) Alternative Trading was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Alternative Trading, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, and cryptocurrency via an alternative trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). (7) Digital Transformation was established to be a Preferred Technology Partner and Application Development Solution for mid cap brands in various industries including the direct selling and affiliate marketing sector. Digital improves marketing, communications and operations processes with custom software development and implementation. (8) The Secure Living division has developed a plan for fully sustainable, secure, connected, and healthy living communities with homes incorporating advanced technology, energy efficiency, and quality of life living environments both for new construction and renovations for single and multi-family residential housing. (9) The Alternative Energy group was established to help lead the Company’s future in the clean energy business that focuses on environmentally responsible and sustainable measures. Alset Energy, Inc, the holding company for this group, and its wholly owned subsidiary, Alset Solar, Inc., pursue utility-scale solar farms to serve US regional power grids and to provide underutilized properties with small microgrids for independent energy. On May 13, 2021, Sentinel Brokers, LLC. (“Sentinel LLC”), subsidiary of the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 % equity position of Sentinel Brokers Company, Inc. (“Sentinel Co.”), a company registered in the state of New York, and in December 2022, Sentinel LLC exercised this option to increase its equity position to 75 %. Sentinel is a broker-dealer operating primarily as a fiduciary intermediary, facilitating intuitional trading of municipal and corporate bonds as well as preferred stock, and is registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). The accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly our consolidated financial position as of June 30, 2023 and December 31, 2022, and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial statements and the notes included in our latest annual report on Form 10-K for the fiscal year ended December 31, 2022 (“Form 10-K”), and our other reports on file with the Securities and Exchange Commission (the “SEC”). Principles of Consolidation Deconsolidation of Sharing Services Global Corporation - 7 81 s a result, SHRG, whose operations represented a significant portion of our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective as of May 1, 2023 (the “Deconsolidation”). The consolidated statement of operations for the fiscal quarter ended June 30, 2023, therefore includes one month of activity related to SHRG prior to the Deconsolidation. Subsequent to April 30, 2023 the assets and liabilities of SHRG are no longer included within our consolidated balance sheets. Any discussions related to results, operations, and accounting policies associated with SHRG refer to the periods prior to the Deconsolidation. Upon Deconsolidation, we recognized a loss before income taxes of approximately $ 29,196,000 148,000 Reclassifications Use of Estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the accounts receivable, convertible notes receivable, inventory, fair values of investments, intangible assets and goodwill, useful lives of intangible assets and property and equipment, fair values of options and warrants to purchase the Company’s common stock, preferred stock, deferred revenue and income taxes, among others. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Cash Equivalents Accounts/Rents Receivable 3,390,000 29,000 Notes receivable, unearned interest, and related recognition Investments For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments. Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. Inventory 57,000 742,000 Impairment of Long-Lived Assets and Goodwill Business Combinations (Loss) Earnings Per Common Share 3,333 3,556 11,930 Concentration of Credit Risk - As of December 31, 2022, two customers accounted for approximately 14 6 36 17 As of June 30, 2023, two customers accounted for approximately 19 5 55 14 Income Taxes Allowance For Loans And Lease Losses ASU No.2016-13 – Credit Losses” Going Concern 10.0 Aside from its $ 10.0 11.6 9.3 55 15 40.2 The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, continued growth among our operating segments, and tightly controlling operating costs and reducing spending growth rates wherever possible to return to profitability. In addition, the Company has taken steps, and will continue to take measures, to materially reduce the expenses and cash burn at all corporate and business line levels. At the Company’s current operating levels and capital usage, we believe that without any further acquisition or investments, our $ 10.0 11.6 9.3 |
Revenue
Revenue | 6 Months Ended |
Jun. 30, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | 2. Revenue The Company recognizes its products and services revenue based on when the title passes to the customer or when the service is completed and accepted by the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for shipped product or service provided. Sales and other taxes billed and collected from customers are excluded from revenue. The Company recognizes rental income associated with its REIT, net of amortization of favorable/unfavorable lease terms relative to market and includes rental abatements and contractual fixed increases attributable to operating leases, where collection has been considered probable, on a straight-line basis over the term of the related lease. The Company recognizes net investment income from its investment banking line of business as interest owed to the Company occurs. The Company generates revenue from its direct marketing line of business primarily through internet sales and recognizes revenue as items are shipped. As of June 30, 2023, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the asset that the Company would have otherwise recognized is one year or less. Accounts/Rents Receivable The Company extends credit to its customers in the normal course of business. The Company performs ongoing credit evaluations and generally does not require collateral. Payment terms are generally 30 days but up to net 105 for certain customers. The Company carries its trade accounts receivable at invoice amounts and its rent receivables at contract amounts, less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for doubtful accounts based upon management’s estimates that include a review of the history of past write-offs and collections and an analysis of current credit conditions. At June 30, 2023, and December 31, 2022, the Company established a reserve for doubtful accounts of approximately $ 3,390,000 29,000 3,361,000 Selling, general and administrative (including stock-based compensation) on the accompanying Condensed Consolidation of Operations. Sales Commissions Sales commissions are expensed as incurred for contracts with an expected duration of one year or less. There were no sales commissions capitalized as of June 30, 2023. Shipping and Handling Costs Costs incurred by the Company related to shipping and handling are included in cost of products sold. Amounts charged to customers pertaining to these costs are reflected as revenue. See Note 15 for disaggregated revenue information. |
Inventory
Inventory | 6 Months Ended |
Jun. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Inventory | 3. Inventory Inventory consisted of the following as of: Schedule of Inventory June 30, 2023 December 31, 2022 Finished Goods $ 3,226,000 $ 6,779,000 Work in Process 749,000 403,000 Raw Materials 1,381,000 1,281,000 Inventory Gross $ 5,357,000 $ 8,463,000 Less allowance for obsolescence (57,000 ) (742,000 ) Inventory Net $ 5,300,000 $ 7,721,000 |
Notes Receivable
Notes Receivable | 6 Months Ended |
Jun. 30, 2023 | |
Receivables [Abstract] | |
Notes Receivable | 4. Notes Receivable Note 1 On February 8, 2021, the Company entered into a convertible promissory note (“Note 1”) with Borrower 1, a company registered in Gibraltar. The Company loaned the principal sum of $ 800,000 4 Note 2 On May 14, 2021, DSS Pure Air, Inc. a subsidiary of the Company entered a convertible promissory note (“Note 2”) with Borrower 2, a company registered in the state of Texas. Note 3 has an aggregate principal balance up to $ 5,000,000 6.65 May 1, 2023 Note 2 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Borrower 2 with the maximum principal amount equal to 18% of the total equity position of Borrower 2 at conversion. 5,544,000 5,420,000 2,884,000 Note 3 On September 23, 2021, APB entered into refunding bond anticipatory note (“Note 3”) with Borrower 3, which operates as a conservation and reclamation district pursuant to Chapter 3891, Texas Special District Local Laws Code; Chapter 375, Texas Local Government Code; and Chapter 49, Texas Water Code. The District Note was in the sum of $ 3,500,000 5.59 September 22, 2022 3,802,000 3,701,000 Note 4 On October 25, 2021, APB entered into a loan agreement (“Note 4”) with Borrower 4, a company registered in the state of Utah. Note 4 has an initial aggregate principal balance up to $ 1,000,000 , to be funded at the request of Borrower 4, with an option to increase the maximum principal borrowing to $ 3,000,000 . Note 4, which incurs interest at a rate of 8.0 % with principal and interest due at the maturity date of October 25, 2022 . This note contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest. APB, as holder of Note 4, has the right to elect one member to the Board of Managers. This note is in default and the outstanding principal and interest of approximately $ 884,000 was reserved for fully as of December 31, 2022. Note 5 On May 14, 2021, APB extended the credit (“Note 5”) to an individual (“Borrower 5”) in the form of two promissory notes for $ 250,000 10,000 12.5 May 15, 2023 262,000 9,000 252,000 9,000 Note 6 On October 27, 2021, HWH World, Inc., a subsidiary of the Company entered a revolving loan commitment (“Note 6”) with Borrower 8, a company registered in Taiwan. The outstanding principal and interest at June 30, 2023 and December 31, 2022 is $ 68,000 63,000 note was amended in April 2022 to borrow up to $ 102,000 18 Note 7 On December 28, 2021, APB entered into a promissory note (“Note 7”) with Borrower 7, a company registered in the state of California. Note 7 has a principal balance of $ 700,000 12.0 December 28, 2022 May 31, 2023 612,000 701,000 Note 8 On January 24, 2022, APB and Borrower 8 entered into a promissory note (“Note 8”) in the principal sum of $ 100,000 6 January 2024 99,000 106,000 Note 9 On March 2, 2022, APB and Borrower 9, a corporation organized under the laws of the Republic of Korea entered into a promissory note (“Note 9”). Under the terms of Note 9, APB at its discretion, may lend up to the principal sum of $ 893,000 8 March 2024 435,000 14,000 874,000 25,000 Note 10 On May 9, 2022, DSS PureAir and Borrower 2 entered into a promissory note (“Note 10”) in the principal sum of $ 210,000 10 February 9, 2023 224,000 213,000 Note 11 On August 29, 2022, DSS Financial Management Inc and Borrower 11 entered into a promissory note (“Note 11A”) in the principal sum of $ 100,000 with interest of 8 %, is due in three quarterly installments beginning on September 14, 2022. All unpaid principal and interest is due on August 29, 2025 . The outstanding principal and interest at June 30, 2023 and December 31, 2023 approximates $ 99,000 , and $ 100,000 is included in Notes receivable on the accompanying consolidate balance sheet. Borrower 11 entered into a second promissory note (Note 11B) on May 8, 2023 in the principal sum of $ 100,000 2 10.25 102,000 Note 12 On July 26, 2022, APB and Borrower 12 entered into a promissory note (“Note 12”) in the principal sum of $ 1,000,000 8 July 26, 2024 861,000 40,000 924,000 66,000 Note 13 On June 15, 2022, Decentralized and Borrower 13 entered into a convertible promissory note (“Note 13”) in the principal sum of $ 27,000,000 8 0.03 June 14, 2024 Note 14 On February 19, 2021, Impact BioMedical, Inc, a subsidiary of the Company, entered into a promissory note (Note 14) with Borrower 14. The Company loaned the principal sum of $ 206,000 6.5 August 19, 2022 204,000 206,000 16,000 190,000 Note 15 On May 8, 2023, DSS Financial Management Inc and Borrower 15 entered into a promissory note (“Note 15”) in the principal sum of $ 102,000 2 10.5 May 5, 2026 102,000 36,000 65,000 Note 16 On June 27, 2023, Decentralized and Borrower 16 entered into a convertible promissory note (“Note 16”) in the principal sum of $ 1,400,000 300,000 10 September, 1, 2024 1,100,000 Note 17 On March 31,2023, DSS Biohealth Security, Inc and Borrower 17 entered into a promissory note (“Note 17”) in the principal sum of $ 140,000 March 31, 2025 127,000 83,000 44,000 |
Financial Instruments
Financial Instruments | 6 Months Ended |
Jun. 30, 2023 | |
Investments, All Other Investments [Abstract] | |
Financial Instruments | 5. Financial Instruments Cash, Cash Equivalents, Restricted Cash and Marketable Securities The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of June 30, 2023, and December 31, 2022: Schedule of Cash and Marketable Securities by Significant Investment Category 2023 Unrealized Gain/ Fair Cash and Cash Marketable Cost (Loss) Value Equivalents Securities Cash $ 9,971,000 $ - $ 9,971,000 $ 9,971,000 $ - Level 1 Money Market Funds $ 62,000 - 62,000 62,000 - Marketable Securities 15,165,000 (3,590,000 ) 11,575,000 - 11,575,000 Total $ 25,198,000 $ (3,590,000 ) $ 21,608,000 $ 10,033,000 $ 11,575,000 2022 Unrealized Gain/ Fair Cash and Cash Marketable Cost (Loss) Value Equivalents Securities Investments Cash $ 19,226,000 $ - $ 19,226,000 $ 19,226,000 $ - $ - Level 1 Money Market Funds 64,000 - 64,000 64,000 - - Marketable Securities 36,263,000 (3,659,000 ) 27,307,000 - 27,307,000 - Level 2 Warrants 3,318,000 - 140,000 - - 140,000 Convertible securities 1,023,000 - 39,000 - - 39,000 Total $ 59,894,000 $ (3,659,000 ) $ 46,776,000 $ 19,290,000 $ 27,307,000 $ 179,000 The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio. |
Provision for Credit Losses
Provision for Credit Losses | 6 Months Ended |
Jun. 30, 2023 | |
Provision For Credit Losses | |
Provision for Credit Losses | 6. Provision for Credit Losses Effective December 31, 2022, the Company adopted amended accounting guidance “ ASU No.2016-13 – Credit Losses” As of December 31, 2022, and June 30, 2023 we have reviewed the entire loan portfolio as well as all financial assets of the Company for the purpose of evaluating the loan portfolio and the loan balances, including a review of individual and collective portfolio loan quality, loan(s) performance, including past due status and covenant defaults, assessment of the ability of the borrower to repay the loan on the loan terms, whether any loans should be placed on nonaccrual or returned to accrual, any concentrations in any single borrower and/or industry that we might need to further manage, and if any specific or general loan loss reserve should be established for the entire loan portfolio or for any specific loan. We analyzed the loan loss reserve from three basis: general loan portfolio reserves; industry portfolio reserves, and specific loan loss reserves. For the three and six months ended June 30, 2023, the Company recorded a Loan loss reserve of approximately $ 3,757,000 General Loan Portfolio Reserve - 145,000 199,000 Industry Portfolio Reserves - Specific Loan Reserves 884,000 . As of December 31, 2022 and June 30, 2023 we have recorded a specific loan loss reserve for the full balance due the Company. As of December 31, 2022 and June 30, 2023, the Company reserved for principal and of $ 27,831,000 2,884,000 |
Held For Sale Assets and Liabil
Held For Sale Assets and Liabilities | 6 Months Ended |
Jun. 30, 2023 | |
Held For Sale Assets And Liabilities | |
Held For Sale Assets and Liabilities | 7. Held For Sale Assets and Liabilities On July 1 st 1000 0.01 711,000 The following table identifies the assets and liabilities of HWH World Inc sale for the period ending June 30, 2023: Schedule of Assets and Liabilities Discontinued Operations June 30, 2023 Current assets: Cash and cash equivalents $ 135,000 Accounts receivable, net 423,000 Inventory 807,000 Current portion of notes receivable 68,000 Prepaid expenses and other current assets 91,000 Total current assets 1,524,000 Property, Plant & Equipment 117,000 Right of use assets 70,000 Other Intangible assets 293,000 Total assets $ 2,004,000 Current liabilities: Accounts payable $ 978,000 Accrued expenses and deferred revenue 21,000 Current Portion of Lease liability 130,000 Total current liabilities 1,129,000 Long Term Lease liability 59,000 Total liabilities $ 1,188,000 |
Investments
Investments | 6 Months Ended |
Jun. 30, 2023 | |
Investments, All Other Investments [Abstract] | |
Investments | 8. Investments Alset International Limited related party The Company owns 127,179,291 4 1,501,000 3,319,000 1,945,000 1,068,000 West Park Capital, Inc. On December 30, 2020, the Company signed a binding letter of intent with West Park Capital, Inc (“West Park”) and TBD where the parties agreed to prepare a note and stock exchange agreement whereby DSS will assign the TBD Note to West Park and West Park shall issue to DSS a stock certificate reflecting 7.5 500,000 BMI Capital International LLC On September 10, 2020, the Company’s wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware corporation (“BMIF”) and BMI Capital International LLC, a Texas limited liability company (“BMIC”) whereas DSS Securities, Inc. purchased 14.9 100,000 10 100,000 24.9 20 22,000 26,000 BMIC is a broker-dealer registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). The Company’s chairman of the board and another independent board member of the Company also have ownership interest in BMIC. BioMed Technologies Asia Pacific Holdings Limited On December 19, 2020, Impact BioMedical, a wholly owned subsidiary of the Company, entered into a subscription agreement (the “Subscription Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 4.99 632,000 Under the terms of the Distribution Agreement, the Company will have exclusive rights to distribute the products within the United States, Canada, Singapore, Malaysia, and South Korea and non-exclusive distribution rights in all other countries. In exchange, the Company agreed to certain obligations, including mutual marketing obligations to promote sales of the products. This agreement is for ten years with a one year auto-renewal feature. Vivacitas Oncology, Inc. On March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the “Vivacitas Agreement #1”) with Vivacitas Oncology Inc. (“Vivacitas”), to purchase 500,000 1.00 1,500,000 1.00 1.00 500,000 2,480,000 2,480,000 250,000 On April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $ 1.00 120,000 On July 22, 2021, the Company exercised 1,000,000 1,000,000 16 100 4,100,000 Stemtech Corporation (Sharing Services Global Corp) In September 2021, the Company’s subsidiary SHRG, Stemtech Corporation (“Stemtech”) and Globe Net Wireless Corp. (“GNTW”) entered into a Securities Purchase Agreement (the “SPA”) pursuant to which SHRG invested $ 1.4 million in Stemtech in exchange for: (a) a Convertible Promissory Note in the amount of $ 1.4 million in favor of the Company (the “Convertible Note”) and (b) a detachable Warrant to purchase shares GNTW common stock (the “GNTW Warrant”). Stemtech is a subsidiary of GNTW. As an inducement to enter into the SPA, GNTW agreed to pay to the SHRG an origination fee of $ 500,000 , payable in shares of GNTW’s common stock. The Convertible Note matures on September 9, 2024 , bears interest at the annual rate of 10 %, and is convertible, at the option of the holder, into shares of GNTW’s common stock at a conversion rate calculated based on the closing price per share of GNTW’s common stock during the 30-dayperiod ended September 19, 2021. The GNTW Warrant expires on September 13, 2024 and conveys the right to purchase up to 1.4 million shares of GNTW’s common stock at a purchase price calculated based on the closing price per share of GTNW’s common stock during the 10-day period ended September 13, 2021. In September 2021, GNTW issued to the Company 154,173 shares of its common stock, or less than 1% of the shares of GNTW then issued and outstanding, in payment of the origination fee. In November 2021, Globe Net Wireless Corp. changed its corporate name to Stemtech Corporation. In connection therewith, the investee’s common stock is now traded under the symbol “STEK”. The SHRG carries its investment in the Convertible Note, the GNTW Warrant and the shares of GNTW common stock at fair value in accordance with GAAP. As of June 30, 2023 and December 31, 2022 the investment in the GNTW Warrant and Convertible Note, were valued at $ 0 and $ 44,000 and $ 0 and $ 39,000 respectively. In September 2021, SHRG entered into a Membership Unit Purchase Agreement pursuant to which the SHRG acquired a 30.75 1,537,000 100 |
Acquisitions
Acquisitions | 6 Months Ended |
Jun. 30, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Acquisitions | 9. Acquisitions Sentinel Brokers Company, Inc. On May 13, 2021, Sentinel Brokers, LLC. (“Sentinel LLC”), subsidiary of the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 300,000 750,000 1,050,000 Investments—Equity Method and Joint Ventures 50.1 75 The following summary, prepared on a proforma basis, combines the consolidated results of operations of the Company with those of Sentinel Co as if the acquisition took place on January 1. The pro forma consolidated results include the impact of certain adjustments. Schedule of Business Acquisition, Pro Forma Information 2022 (unaudited) Revenue $ 49,076,804 Net loss $ (61,680,088 ) Basic loss per share $ (0.55 ) Diluted loss per share $ (0.55 ) We are currently in the process of completing the purchase price accounting and related allocations associated with the acquisition of Sentinel Co. Assets included in this acquisition are cash of $ 3,977,000 344,000 1,000 1,274,000 Sentinel is a broker-dealer operating primarily as a fiduciary intermediary, facilitating intuitional trading of municipal and corporate bonds as well as preferred stock, and is registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). |
Short-Term and Long-Term Debt
Short-Term and Long-Term Debt | 6 Months Ended |
Jun. 30, 2023 | |
Debt Disclosure [Abstract] | |
Short-Term and Long-Term Debt | 10. Short-Term and Long-Term Debt DSS, Inc Promissory Notes - 200,000 8.0 5.00 200,000 On March 16, 2021, American Medical REIT, Inc. received loan proceeds in the amount of approximately $ 110,000 1 111,000 On May 20, 2021, Premier Packaging entered into master loan and security agreement (“BOA Note”) with Bank of America, N.A. (“BOA”) to secure financing approximating $ 3,710,000 3,172,000 3,406,000 4.63 485,000 2,687,000 On August 1, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $ 6,155,000 5,105,000 4.25 The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5 year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months 2,829,000 4.25 40,000 13.62-acre site. The purchase price has been allocated as $ 4,640,000 1,600,000 325,000 585,000 3 4,696,000 168,000 4,590,000 61,000 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 512,000 3,000,000 On October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 , with interest to be charged at a variable rate to be calculated at the maturity date. The Wilson Loan matures on October 12, 2022 , and contains an auto renewal period of nine months. This loan was funded during March 2022. As of June 30, 2023 $ 1,997,000 is included in the Current portion of long-term debt, net on the consolidated balance sheet. As of December 31, 2022 $ 3,008,000 is included in the Current portion of long-term debt, net on the consolidated balance sheet. On November 2, 2021, AMRE LifeCare entered into a loan agreement (“LifeCare Agreement”) with Pinnacle Bank, (“Pinnacle Bank”) in the amount of $ 40,300,000 62,000,000 32,100,000 12,100,000 1,500,000 15,901,000 1 11 52,407,000 The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28%, with the first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in full 8.46 November 2, 2023 November 2, 2024 40,193,000 270,000 40,380,000 106,000 297,000 2,418,000 In November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”), a related party, for the principal amount of $ 8,350,000 8 matures in December 2023 8,805,000 21,366,177 8,350,000 119,000 455,000 346,000 On March 17, 2022, AMRE Winter Haven, LLC (“AMRE Winter Haven”) and Pinnacle Bank (“Pinnacle”) entered into a term loan (“Pinnacle Loan”) whereas Pinnacle lent to AMRE Winter Haven the principal sum of $ 2,990,000 March 7, 2024 4,500,000 3,200,000 1,000,000 222,000 29,000 5 4,450,000 25 4.28 52,000 2,951,000 interest, net of debt issuance costs of $60,000, approximates $2,952,000 and is included in long-term debt, net on the accompanying consolidated balance sheet at December 31, 2022 . 24,000 153,000 On March 30, 2023, Premier Packaging, a subsidiary of the Company entered into a loan and security agreement with Union Bank & Trust Company for the principal amount of $ 790,000 7.44 14,000 773,000 110,000 663,000 A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to June 30, 2023, are as follows: Schedule of Notes Payable and Long-term Debt Year Amount 2023 $ 47,206,000 2024 3,801,000 2025 858,000 2026 901,000 2027 947,000 Thereafter 711,000 |
Lease Liability
Lease Liability | 6 Months Ended |
Jun. 30, 2023 | |
Lease Liability | |
Lease Liability | 11. Lease Liability The Company has operating leases predominantly for operating facilities. As of June 30, 2023, the remaining lease terms on our operating leases range from less than one to twelve years. Renewal options to extend our leases have not been exercised due to uncertainty. Termination options are not reasonably certain of exercise by the Company. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants. There are no significant finance leases as of June 30, 2023. Future minimum lease payments as of June 30, 2023, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2023 633,000 2024 950,000 2025 803,000 2026 794,000 2027 808,000 2028 824,000 After 4,675,000 Total lease payments 9,487,000 Less: Imputed Interest (1,734,000 ) Present value of remaining lease payments $ 7,753,000 Current $ 633,000 Noncurrent $ 7,120,000 Weighted-average remaining lease term (years) 13.9 Weighted-average discount rate 4.3 % In March of 2022, Premier Packaging began leasing its relocated manufacturing facilities to West Henrietta, New York. This lease contains an escalating payment clause, ranging from $ 61,000 78,000 |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 12. Commitments and Contingencies License Agreement In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $ 1,250,000 |
Stockholders_ Equity
Stockholders’ Equity | 6 Months Ended |
Jun. 30, 2023 | |
Equity [Abstract] | |
Stockholders’ Equity | 13. Stockholders’ Equity Sales of Equity On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 On March 10, 2022, the Company issued 894,084 340,000 On May 5, 2022, the Company issued 63,205 29,000 On May 25, 2022, the Company issued 15,389,995 5,848,000 On May 17, 2022, the shareholders of the Company approved the issuance of up to 21,366,177 8,350,000 367,000 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 0.41 On April 10, 2023 the Company issued 1,247,078 shares of common stock to Mr. Frank Heuszel, CEO of DSS, pursuant to his employment agreement. These shares were issued to settle a previously recorded liability. Stock-Based Compensation - 2,000 |
Supplemental Cash Flow Informat
Supplemental Cash Flow Information | 6 Months Ended |
Jun. 30, 2023 | |
Supplemental Cash Flow Elements [Abstract] | |
Supplemental Cash Flow Information | 14. Supplemental Cash Flow Information The following table summarizes supplemental cash flows for the six-months ended June 30, 2023, and 2022: Schedule of Supplemental Cash Flow Information 2023 2022 Cash paid for interest $ 1,402,000 $ 1,499,000 |
Segment Information
Segment Information | 6 Months Ended |
Jun. 30, 2023 | |
Segment Reporting [Abstract] | |
Segment Information | 15. Segment Information The Company’s nine businesses lines are organized, managed, and internally reported as five Approximate information concerning the Company’s operations by reportable segment for the three and six months ended June 30, 2023 and 2022 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Product Commercial Direct Three Months Ended June 30, 2023 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 3,626,000 $ 197,000 $ 1,572,000 $ - $ 1,838,000 $ - $ 7,233,000 Interest expense 47,000 - - - 91,000 - 138,000 Interest income - - 280,000 49,000 78,000 - 407,000 Net Loss (income) from continuing operations (205,000 ) (1,213,000 ) (28,074,000 ) (3,934,000 ) (4,413,000 ) 116,000 (37,723,000 ) Capital expenditures 4,000 - (4,000 ) 12,000 7,000 - 19,000 Identifiable assets 23,080,000 41,324,000 7,159,000 49,952,000 71,610,000 9,619,000 202,744,000 Assets held for sale - - 2,004,000 - - - 2,004,000 Product Commercial Direct Three Months Ended June 30, 2022 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 3,599,000 $ 831,000 $ 6,111,000 $ 94,000 $ 823,000 $ 313,000 $ 11,771,000 Interest expense 34,000 - (321,000 ) - 408,000 - 121,000 interest Income 1,000 - 2,000 91,000 34,000 11,000 139,000 Net income (loss) from continuing operations 365,000 25,000 892,000 (673,000 ) (3,332,000 ) (2,687,000 ) (5,410,000 ) Capital expenditures 254,000 - 12,000 - 2,000 1,000 269,000 Identifiable assets 26,688,000 52,416,000 52,267,000 56,524,000 85,436,000 9,617,000 282,948,000 Product Commercial Direct - - - - Six Months Ended June 30, 2023 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 9,661,000 $ 314,000 $ 5,566,000 $ - $ 3,523,000 $ - $ 19,064,000 Interest expense 86,000 - - - 302,000 - 388,000 Interest income - - 285,000 143,000 110,000 - 538,000 Net income (loss) from continuing operations 491,000 (1,777,000 ) (31,260,000 ) (4,782,000 ) (6,441,000 ) (2,588,000 ) (46,357,000 ) Capital expenditures 580,000 - - 17,000 35,000 (19,000 ) 613,000 Identifiable assets 23,080,000 41,324,000 7,159,000 49,952,000 71,610,000 9,619,000 202,744,000 Assets held for sale - - 2,004,000 - - - 2,004,000 Product Commercial Direct Six Months Ended June 30, 2022 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 7,168,000 $ 960,000 $ 13,043,000 $ 94,000 $ 2,497,000 $ 302,000 $ 24,064,000 Interest expense 58,000 - - - 1,441,000 - 1,499,000 Stock based compensation 1,000 - - - - 3,000 4,000 Net income (loss) from continuing operations 323,000 207,000 (3,472,000 ) (1,289,000 ) (5,838,000 ) (4,292,000 ) (14,361,000 ) Capital expenditures 943,000 - 14,000 - 15,000 4,000 976,000 Identifiable assets 26,688,000 52,416,000 52,267,000 56,524,000 85,436,000 9,617,000 282,948,000 The following tables disaggregate our business segment revenues by major source: Printed Products Revenue Information: Schedule of Disaggregation of Revenue Three months ended June 30, 2023 Packaging Printing and Fabrication $ 3,571,000 Commercial and Security Printing 55,000 Total Printed Products $ 3,626,000 Three months ended June 30, 2022 Packaging Printing and Fabrication $ 3,952,000 Commercial and Security Printing 96,000 Total Printed Products $ 4,048,000 Six months ended June 30, 2023 Packaging Printing and Fabrication $ 9,341,000 Commercial and Security Printing 320,000 Total Printed Products $ 9,661,000 Six months ended June 30, 2022 Packaging Printing and Fabrication $ 7,468,000 Commercial and Security Printing 149,000 Total Printed Products $ 7,617,000 Direct Marketing Three months ended June 30, 2023 Direct Marketing Internet Sales $ 1,572,000 Total Direct Marketing $ 1,572,000 Three months ended June 30, 2022 Direct Marketing Internet Sales $ 6,070,000 Total Direct Marketing $ 6,070,000 Six months ended June 30, 2023 Direct Marketing Internet Sales $ 5,566,000 Total Direct Marketing $ 5,566,000 Six months ended June 30, 2022 Direct Marketing Internet Sales $ 13,002,000 Total Direct Marketing $ 13,002,000 Rental Income Three months ended June 30, 2023 Rental income $ 1,543,000 Total Rental Income $ 1,543,000 Three months ended June 30, 2022 Rental income $ 1,508,000 Total Rental Income $ 1,508,000 Six months ended June 30, 2023 Rental income $ 3,228,000 Total Rental Income $ 3,228,000 Six months ended June 30, 2022 Rental income $ 3,171,000 Total Rental Income $ 3,171,000 Net Investment Income Three months ended June 30, 2023 Net Investment Income $ 197,000 Total Investment Income $ 197,000 Three months ended June 30, 2022 Net Investment Income $ 145,000 Total Rental Income $ 145,000 Six months ended June 30, 2023 Net investment income $ 314,000 Total Management fee income $ 314,000 Six months ended June 30, 2022 Net Investment Income $ 274,000 Total Management fee income $ 274,000 Commission Income Three months ended June 30, 2023 Commission income $ 295,000 Total commission income $ 295,000 Three months ended June 30, 2022 Commission income $ - Total commission income $ - Six months ended June 30, 2023 Commission income $ 295,000 Total commission income $ 295,000 Six months ended June 30, 2022 Commission income $ - Total commission income $ - |
Related Party Transactions
Related Party Transactions | 6 Months Ended |
Jun. 30, 2023 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 16. Related Party Transactions The Company owns 127,179,291 4 1,501,000 3,319,000 1,945,000 1,068,000 On March 2, 2020, AMRE entered into a $ 200,000 8.0 5.00 200,000 On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (“Seller”) to purchase from the Seller’s its wholly owned subsidiary Impact Oncology PTE Ltd. (“IOPL”) for a purchase price of $ 2,480,000 2,480,000 250,000 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 512,000 3,000,000 On October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 1,997,000 In November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”), a related party, for the principal amount of $ 8,350,000 8 matures in December 2023 8,805,000 21,366,177 8,350,000 119,000 On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 In October 2017, Sharing Services issued a Convertible Promissory Note in the principal amount of $ 50,000 333,333 333,333 0.15 78,635.62 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 0.34 On May 17, 2022, the shareholders of the Company approved the issuance of up to 21,366,177 8,350,000 367,000 |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | 17. Subsequent Events The Company has evaluated all subsequent events and transactions through August 14, 2023, the date that the condensed consolidated financial statements were available to be issued and noted no subsequent events requiring financial statement recognition or disclosure other than what was identified in Note 7. |
Nature of Operations and Basi_2
Nature of Operations and Basis of Presentation and Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Principles of Consolidation | Principles of Consolidation Deconsolidation of Sharing Services Global Corporation - 7 81 s a result, SHRG, whose operations represented a significant portion of our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective as of May 1, 2023 (the “Deconsolidation”). The consolidated statement of operations for the fiscal quarter ended June 30, 2023, therefore includes one month of activity related to SHRG prior to the Deconsolidation. Subsequent to April 30, 2023 the assets and liabilities of SHRG are no longer included within our consolidated balance sheets. Any discussions related to results, operations, and accounting policies associated with SHRG refer to the periods prior to the Deconsolidation. Upon Deconsolidation, we recognized a loss before income taxes of approximately $ 29,196,000 148,000 |
Reclassifications - Certain amounts on the accompanying condensed consolidated cash flows have been reclassified to conform to current period presentation. | Reclassifications |
Use of Estimates | Use of Estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the accounts receivable, convertible notes receivable, inventory, fair values of investments, intangible assets and goodwill, useful lives of intangible assets and property and equipment, fair values of options and warrants to purchase the Company’s common stock, preferred stock, deferred revenue and income taxes, among others. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. |
Cash Equivalents | Cash Equivalents |
Accounts/Rents Receivable | Accounts/Rents Receivable 3,390,000 29,000 |
Notes receivable, unearned interest, and related recognition | Notes receivable, unearned interest, and related recognition |
Investments | Investments For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. |
Inventory | Inventory 57,000 742,000 |
Impairment of Long-Lived Assets and Goodwill | Impairment of Long-Lived Assets and Goodwill |
Business Combinations | Business Combinations |
(Loss) Earnings Per Common Share | (Loss) Earnings Per Common Share 3,333 3,556 11,930 |
Concentration of Credit Risk | Concentration of Credit Risk - As of December 31, 2022, two customers accounted for approximately 14 6 36 17 As of June 30, 2023, two customers accounted for approximately 19 5 55 14 |
Income Taxes | Income Taxes |
Allowance For Loans And Lease Losses | Allowance For Loans And Lease Losses ASU No.2016-13 – Credit Losses” |
Going Concern | Going Concern 10.0 Aside from its $ 10.0 11.6 9.3 55 15 40.2 The Company’s management intends to take actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, continued growth among our operating segments, and tightly controlling operating costs and reducing spending growth rates wherever possible to return to profitability. In addition, the Company has taken steps, and will continue to take measures, to materially reduce the expenses and cash burn at all corporate and business line levels. At the Company’s current operating levels and capital usage, we believe that without any further acquisition or investments, our $ 10.0 11.6 9.3 |
Inventory (Tables)
Inventory (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory | Inventory consisted of the following as of: Schedule of Inventory June 30, 2023 December 31, 2022 Finished Goods $ 3,226,000 $ 6,779,000 Work in Process 749,000 403,000 Raw Materials 1,381,000 1,281,000 Inventory Gross $ 5,357,000 $ 8,463,000 Less allowance for obsolescence (57,000 ) (742,000 ) Inventory Net $ 5,300,000 $ 7,721,000 |
Financial Instruments (Tables)
Financial Instruments (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Investments, All Other Investments [Abstract] | |
Schedule of Cash and Marketable Securities by Significant Investment Category | The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of June 30, 2023, and December 31, 2022: Schedule of Cash and Marketable Securities by Significant Investment Category 2023 Unrealized Gain/ Fair Cash and Cash Marketable Cost (Loss) Value Equivalents Securities Cash $ 9,971,000 $ - $ 9,971,000 $ 9,971,000 $ - Level 1 Money Market Funds $ 62,000 - 62,000 62,000 - Marketable Securities 15,165,000 (3,590,000 ) 11,575,000 - 11,575,000 Total $ 25,198,000 $ (3,590,000 ) $ 21,608,000 $ 10,033,000 $ 11,575,000 2022 Unrealized Gain/ Fair Cash and Cash Marketable Cost (Loss) Value Equivalents Securities Investments Cash $ 19,226,000 $ - $ 19,226,000 $ 19,226,000 $ - $ - Level 1 Money Market Funds 64,000 - 64,000 64,000 - - Marketable Securities 36,263,000 (3,659,000 ) 27,307,000 - 27,307,000 - Level 2 Warrants 3,318,000 - 140,000 - - 140,000 Convertible securities 1,023,000 - 39,000 - - 39,000 Total $ 59,894,000 $ (3,659,000 ) $ 46,776,000 $ 19,290,000 $ 27,307,000 $ 179,000 |
Held For Sale Assets and Liab_2
Held For Sale Assets and Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Held For Sale Assets And Liabilities | |
Schedule of Assets and Liabilities Discontinued Operations | The following table identifies the assets and liabilities of HWH World Inc sale for the period ending June 30, 2023: Schedule of Assets and Liabilities Discontinued Operations June 30, 2023 Current assets: Cash and cash equivalents $ 135,000 Accounts receivable, net 423,000 Inventory 807,000 Current portion of notes receivable 68,000 Prepaid expenses and other current assets 91,000 Total current assets 1,524,000 Property, Plant & Equipment 117,000 Right of use assets 70,000 Other Intangible assets 293,000 Total assets $ 2,004,000 Current liabilities: Accounts payable $ 978,000 Accrued expenses and deferred revenue 21,000 Current Portion of Lease liability 130,000 Total current liabilities 1,129,000 Long Term Lease liability 59,000 Total liabilities $ 1,188,000 |
Acquisitions (Tables)
Acquisitions (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Sentinel Brokers Company Inc [Member] | |
Business Acquisition [Line Items] | |
Schedule of Business Acquisition, Pro Forma Information | The following summary, prepared on a proforma basis, combines the consolidated results of operations of the Company with those of Sentinel Co as if the acquisition took place on January 1. The pro forma consolidated results include the impact of certain adjustments. Schedule of Business Acquisition, Pro Forma Information 2022 (unaudited) Revenue $ 49,076,804 Net loss $ (61,680,088 ) Basic loss per share $ (0.55 ) Diluted loss per share $ (0.55 ) |
Short-Term and Long-Term Debt (
Short-Term and Long-Term Debt (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Notes Payable and Long-term Debt | A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to June 30, 2023, are as follows: Schedule of Notes Payable and Long-term Debt Year Amount 2023 $ 47,206,000 2024 3,801,000 2025 858,000 2026 901,000 2027 947,000 Thereafter 711,000 |
Lease Liability (Tables)
Lease Liability (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Lease Liability | |
Schedule of Future Minimum Lease Payments | Future minimum lease payments as of June 30, 2023, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2023 633,000 2024 950,000 2025 803,000 2026 794,000 2027 808,000 2028 824,000 After 4,675,000 Total lease payments 9,487,000 Less: Imputed Interest (1,734,000 ) Present value of remaining lease payments $ 7,753,000 Current $ 633,000 Noncurrent $ 7,120,000 Weighted-average remaining lease term (years) 13.9 Weighted-average discount rate 4.3 % |
Supplemental Cash Flow Inform_2
Supplemental Cash Flow Information (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Supplemental Cash Flow Elements [Abstract] | |
Schedule of Supplemental Cash Flow Information | The following table summarizes supplemental cash flows for the six-months ended June 30, 2023, and 2022: Schedule of Supplemental Cash Flow Information 2023 2022 Cash paid for interest $ 1,402,000 $ 1,499,000 |
Segment Information (Tables)
Segment Information (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Operations by Reportable Segment | Approximate information concerning the Company’s operations by reportable segment for the three and six months ended June 30, 2023 and 2022 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Product Commercial Direct Three Months Ended June 30, 2023 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 3,626,000 $ 197,000 $ 1,572,000 $ - $ 1,838,000 $ - $ 7,233,000 Interest expense 47,000 - - - 91,000 - 138,000 Interest income - - 280,000 49,000 78,000 - 407,000 Net Loss (income) from continuing operations (205,000 ) (1,213,000 ) (28,074,000 ) (3,934,000 ) (4,413,000 ) 116,000 (37,723,000 ) Capital expenditures 4,000 - (4,000 ) 12,000 7,000 - 19,000 Identifiable assets 23,080,000 41,324,000 7,159,000 49,952,000 71,610,000 9,619,000 202,744,000 Assets held for sale - - 2,004,000 - - - 2,004,000 Product Commercial Direct Three Months Ended June 30, 2022 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 3,599,000 $ 831,000 $ 6,111,000 $ 94,000 $ 823,000 $ 313,000 $ 11,771,000 Interest expense 34,000 - (321,000 ) - 408,000 - 121,000 interest Income 1,000 - 2,000 91,000 34,000 11,000 139,000 Net income (loss) from continuing operations 365,000 25,000 892,000 (673,000 ) (3,332,000 ) (2,687,000 ) (5,410,000 ) Capital expenditures 254,000 - 12,000 - 2,000 1,000 269,000 Identifiable assets 26,688,000 52,416,000 52,267,000 56,524,000 85,436,000 9,617,000 282,948,000 Product Commercial Direct - - - - Six Months Ended June 30, 2023 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 9,661,000 $ 314,000 $ 5,566,000 $ - $ 3,523,000 $ - $ 19,064,000 Interest expense 86,000 - - - 302,000 - 388,000 Interest income - - 285,000 143,000 110,000 - 538,000 Net income (loss) from continuing operations 491,000 (1,777,000 ) (31,260,000 ) (4,782,000 ) (6,441,000 ) (2,588,000 ) (46,357,000 ) Capital expenditures 580,000 - - 17,000 35,000 (19,000 ) 613,000 Identifiable assets 23,080,000 41,324,000 7,159,000 49,952,000 71,610,000 9,619,000 202,744,000 Assets held for sale - - 2,004,000 - - - 2,004,000 Product Commercial Direct Six Months Ended June 30, 2022 Packaging Lending Marketing Biotechnology Securities Corporate Total Revenue $ 7,168,000 $ 960,000 $ 13,043,000 $ 94,000 $ 2,497,000 $ 302,000 $ 24,064,000 Interest expense 58,000 - - - 1,441,000 - 1,499,000 Stock based compensation 1,000 - - - - 3,000 4,000 Net income (loss) from continuing operations 323,000 207,000 (3,472,000 ) (1,289,000 ) (5,838,000 ) (4,292,000 ) (14,361,000 ) Capital expenditures 943,000 - 14,000 - 15,000 4,000 976,000 Identifiable assets 26,688,000 52,416,000 52,267,000 56,524,000 85,436,000 9,617,000 282,948,000 |
Schedule of Disaggregation of Revenue | Printed Products Revenue Information: Schedule of Disaggregation of Revenue Three months ended June 30, 2023 Packaging Printing and Fabrication $ 3,571,000 Commercial and Security Printing 55,000 Total Printed Products $ 3,626,000 Three months ended June 30, 2022 Packaging Printing and Fabrication $ 3,952,000 Commercial and Security Printing 96,000 Total Printed Products $ 4,048,000 Six months ended June 30, 2023 Packaging Printing and Fabrication $ 9,341,000 Commercial and Security Printing 320,000 Total Printed Products $ 9,661,000 Six months ended June 30, 2022 Packaging Printing and Fabrication $ 7,468,000 Commercial and Security Printing 149,000 Total Printed Products $ 7,617,000 Direct Marketing Three months ended June 30, 2023 Direct Marketing Internet Sales $ 1,572,000 Total Direct Marketing $ 1,572,000 Three months ended June 30, 2022 Direct Marketing Internet Sales $ 6,070,000 Total Direct Marketing $ 6,070,000 Six months ended June 30, 2023 Direct Marketing Internet Sales $ 5,566,000 Total Direct Marketing $ 5,566,000 Six months ended June 30, 2022 Direct Marketing Internet Sales $ 13,002,000 Total Direct Marketing $ 13,002,000 Rental Income Three months ended June 30, 2023 Rental income $ 1,543,000 Total Rental Income $ 1,543,000 Three months ended June 30, 2022 Rental income $ 1,508,000 Total Rental Income $ 1,508,000 Six months ended June 30, 2023 Rental income $ 3,228,000 Total Rental Income $ 3,228,000 Six months ended June 30, 2022 Rental income $ 3,171,000 Total Rental Income $ 3,171,000 Net Investment Income Three months ended June 30, 2023 Net Investment Income $ 197,000 Total Investment Income $ 197,000 Three months ended June 30, 2022 Net Investment Income $ 145,000 Total Rental Income $ 145,000 Six months ended June 30, 2023 Net investment income $ 314,000 Total Management fee income $ 314,000 Six months ended June 30, 2022 Net Investment Income $ 274,000 Total Management fee income $ 274,000 Commission Income Three months ended June 30, 2023 Commission income $ 295,000 Total commission income $ 295,000 Three months ended June 30, 2022 Commission income $ - Total commission income $ - Six months ended June 30, 2023 Commission income $ 295,000 Total commission income $ 295,000 Six months ended June 30, 2022 Commission income $ - Total commission income $ - |
Nature of Operations and Basi_3
Nature of Operations and Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
May 04, 2023 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Dec. 31, 2022 | May 13, 2021 | |
Product Information [Line Items] | ||||||
Common share, issued and outstanding, rate | 81% | |||||
Gain loss on investments | $ 29,196,000 | $ 29,196,000 | ||||
Marketable securities | 148,000 | 148,000 | ||||
Reserve for doubtful accounts | 3,390,000 | 3,390,000 | $ 29,000 | |||
Inventory allowance for obsolescence | 57,000 | 57,000 | 742,000 | |||
Cash | 10,000,000 | 10,000,000 | ||||
Marketable securities | 11,575,000 | 11,575,000 | 27,307,000 | |||
Outstanding principal and interest | 9,300,000 | 9,300,000 | ||||
Current portion of notes receivable | 9,269,000 | 9,269,000 | $ 11,719,000 | |||
Sharing Services Global Corp [Member] | ||||||
Product Information [Line Items] | ||||||
Sale of stock consideration received on transaction | 15,000,000 | |||||
Pinnacle Bank [Member] | ||||||
Product Information [Line Items] | ||||||
Debt instrument, face amount | $ 40,200,000 | $ 40,200,000 | ||||
Impact BioMedical, Inc. [Member] | ||||||
Product Information [Line Items] | ||||||
Ownership percentage | 55% | 55% | ||||
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | ||||||
Product Information [Line Items] | ||||||
Concentration risk percentage | 19% | 14% | ||||
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | ||||||
Product Information [Line Items] | ||||||
Concentration risk percentage | 55% | 36% | ||||
Customer Two [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | ||||||
Product Information [Line Items] | ||||||
Concentration risk percentage | 5% | 6% | ||||
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | ||||||
Product Information [Line Items] | ||||||
Concentration risk percentage | 14% | 17% | ||||
Warrant [Member] | ||||||
Product Information [Line Items] | ||||||
Anti dilutive securities excluded from computation of EPS | 3,333 | 3,556 | ||||
Share-Based Payment Arrangement, Option [Member] | ||||||
Product Information [Line Items] | ||||||
Anti dilutive securities excluded from computation of EPS | 11,930 | |||||
Sentinel Brokers LLC [Member] | ||||||
Product Information [Line Items] | ||||||
Ownership interest rate | 75% | 24.90% | ||||
SHRG [Member] | ||||||
Product Information [Line Items] | ||||||
Ownership interest rate | 7% |
Revenue (Details Narrative)
Revenue (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Reserve for doubtful accounts | $ 3,390,000 | $ 3,390,000 | $ 29,000 | |
Selling, general and administrative | $ 4,000 | |||
Selling, General and Administrative Expenses [Member] | ||||
Selling, general and administrative | $ 3,361,000 | $ 3,361,000 |
Schedule of Inventory (Details)
Schedule of Inventory (Details) - USD ($) | Jun. 30, 2023 | Dec. 31, 2022 |
Inventory Disclosure [Abstract] | ||
Finished Goods | $ 3,226,000 | $ 6,779,000 |
Work in Process | 749,000 | 403,000 |
Raw Materials | 1,381,000 | 1,281,000 |
Inventory Gross | 5,357,000 | 8,463,000 |
Less allowance for obsolescence | (57,000) | (742,000) |
Inventory Net | $ 5,300,000 | $ 7,721,000 |
Notes Receivable (Details Narra
Notes Receivable (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||
Jun. 27, 2023 | May 08, 2023 | Mar. 31, 2023 | Dec. 29, 2022 | Aug. 29, 2022 | Jul. 26, 2022 | Jun. 15, 2022 | May 09, 2022 | Mar. 02, 2022 | Jan. 24, 2022 | Dec. 28, 2021 | Oct. 25, 2021 | Sep. 23, 2021 | May 14, 2021 | Feb. 19, 2021 | Apr. 30, 2022 | Mar. 31, 2023 | Jun. 30, 2023 | Dec. 31, 2022 | Jun. 30, 2022 | Feb. 08, 2021 | |
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Notes receivable current | $ 9,269,000 | $ 11,719,000 | |||||||||||||||||||
Principal and interest outstanding | 9,300,000 | ||||||||||||||||||||
Notes Payable | 1,112,000 | 922,000 | |||||||||||||||||||
Notes payable | 47,206,000 | 47,161,000 | |||||||||||||||||||
Note 1 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 800,000 | ||||||||||||||||||||
Prime plus rate percentage | 4% | ||||||||||||||||||||
Note 2 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 5,000,000 | ||||||||||||||||||||
Prime plus rate percentage | 6.65% | ||||||||||||||||||||
Maturity date | May 01, 2023 | ||||||||||||||||||||
Debt conversion description | Note 2 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Borrower 2 with the maximum principal amount equal to 18% of the total equity position of Borrower 2 at conversion. | ||||||||||||||||||||
Notes receivable current | $ 5,420,000 | $ 5,420,000 | 5,544,000 | ||||||||||||||||||
Principal and interest outstanding | 2,884,000 | ||||||||||||||||||||
Note 3 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 3,500,000 | ||||||||||||||||||||
Prime plus rate percentage | 5.59% | ||||||||||||||||||||
Maturity date | Sep. 22, 2022 | ||||||||||||||||||||
Notes receivable current | 3,701,000 | 3,701,000 | 3,802,000 | ||||||||||||||||||
Note 4 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Prime plus rate percentage | 8% | ||||||||||||||||||||
Maturity date | Oct. 25, 2022 | ||||||||||||||||||||
Notes receivable current | 884,000 | ||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 3,000,000 | ||||||||||||||||||||
Debt description | This note contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest. | ||||||||||||||||||||
Note 4 [Member] | Maximum [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 1,000,000 | ||||||||||||||||||||
Note 5 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Prime plus rate percentage | 12.50% | ||||||||||||||||||||
Maturity date | May 15, 2023 | ||||||||||||||||||||
Note 5 [Member] | Promissory Note One [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 250,000 | ||||||||||||||||||||
Notes receivable current | 262,000 | ||||||||||||||||||||
Notes Payable | 252,000 | 252,000 | |||||||||||||||||||
Note 5 [Member] | Promissory Note Two [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 10,000 | ||||||||||||||||||||
Notes receivable current | 9,000 | ||||||||||||||||||||
Notes Payable | 9,000 | 9,000 | |||||||||||||||||||
Note 6 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Prime plus rate percentage | 18% | ||||||||||||||||||||
Notes receivable current | 63,000 | 63,000 | 68,000 | ||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 102,000 | ||||||||||||||||||||
Debt description | note was amended in April 2022 to borrow up to $102,000 and extend the maturity date through April 2023 bearing interest rate of 18%. The due date of this loan is currently being re-negotiated. | ||||||||||||||||||||
Note 7 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 700,000 | ||||||||||||||||||||
Prime plus rate percentage | 12% | ||||||||||||||||||||
Maturity date | May 31, 2023 | Dec. 28, 2022 | |||||||||||||||||||
Notes receivable current | 701,000 | 701,000 | 612,000 | ||||||||||||||||||
Note 8 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 100,000 | ||||||||||||||||||||
Prime plus rate percentage | 6% | ||||||||||||||||||||
Notes Payable | 99,000 | 106,000 | |||||||||||||||||||
Debt instrument, face amount | January 2024 | ||||||||||||||||||||
Note 9 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 893,000 | ||||||||||||||||||||
Prime plus rate percentage | 8% | ||||||||||||||||||||
Debt instrument, face amount | March 2024 | ||||||||||||||||||||
Outstanding principal and interest | 435,000 | ||||||||||||||||||||
Unamortized origination fees | 25,000 | 14,000 | |||||||||||||||||||
Notes payable | 874,000 | 874,000 | |||||||||||||||||||
Note 10 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 210,000 | ||||||||||||||||||||
Prime plus rate percentage | 10% | ||||||||||||||||||||
Maturity date | Feb. 09, 2023 | ||||||||||||||||||||
Notes receivable current | 224,000 | ||||||||||||||||||||
Notes payable | $ 213,000 | ||||||||||||||||||||
Note 11 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 100,000 | $ 100,000 | |||||||||||||||||||
Prime plus rate percentage | 8% | 2% | |||||||||||||||||||
Maturity date | Aug. 29, 2025 | ||||||||||||||||||||
Notes Payable | 100,000 | 100,000 | |||||||||||||||||||
Notes payable | 99,000 | $ 102,000 | |||||||||||||||||||
Effective rate percentage | 10.25% | ||||||||||||||||||||
Note 12 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 1,000,000 | ||||||||||||||||||||
Prime plus rate percentage | 8% | ||||||||||||||||||||
Maturity date | Jul. 26, 2024 | ||||||||||||||||||||
Outstanding principal and interest | 861,000 | ||||||||||||||||||||
Unamortized origination fees | 40,000 | $ 66,000 | |||||||||||||||||||
Notes payable | 924,000 | ||||||||||||||||||||
Note Thirteen [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 27,000,000 | ||||||||||||||||||||
Prime plus rate percentage | 8% | ||||||||||||||||||||
Maturity date | Jun. 14, 2024 | ||||||||||||||||||||
Conversion price | $ 0.03 | ||||||||||||||||||||
NoteFourteen [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 206,000 | ||||||||||||||||||||
Prime plus rate percentage | 6.50% | ||||||||||||||||||||
Maturity date | Aug. 19, 2022 | ||||||||||||||||||||
Outstanding principal and interest | $ 204,000 | ||||||||||||||||||||
Notes payable | 16,000 | $ 206,000 | $ 190,000 | ||||||||||||||||||
Note Fifteen [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 102,000 | ||||||||||||||||||||
Prime plus rate percentage | 2% | ||||||||||||||||||||
Maturity date | May 05, 2026 | ||||||||||||||||||||
Notes payable | $ 102,000 | ||||||||||||||||||||
Effective rate percentage | 10.50% | ||||||||||||||||||||
Notes payable | $ 36,000 | ||||||||||||||||||||
Notes payable | $ 65,000 | ||||||||||||||||||||
Note Sixteen [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 1,400,000 | ||||||||||||||||||||
Prime plus rate percentage | 10% | ||||||||||||||||||||
Maturity date | Sep. 01, 2024 | ||||||||||||||||||||
Notes payable | 1,100,000 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 300,000 | ||||||||||||||||||||
Note Seventeen [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Principal amount | $ 140,000 | $ 140,000 | |||||||||||||||||||
Maturity date | Mar. 31, 2025 | ||||||||||||||||||||
Notes payable | 127,000 | ||||||||||||||||||||
Notes payable | 83,000 | ||||||||||||||||||||
Notes payable | $ 44,000 |
Schedule of Cash and Marketable
Schedule of Cash and Marketable Securities by Significant Investment Category (Details) - USD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2023 | Dec. 31, 2022 | |
Cash and Cash Equivalents [Line Items] | ||
Adjusted Cost | $ 25,198,000 | $ 59,894,000 |
Unrealized Gain/(Loss) | (3,590,000) | (3,659,000) |
Fair Value | 21,608,000 | 46,776,000 |
Cash and Cash Equivalents | 10,033,000 | 19,290,000 |
Current marketable securities | 11,575,000 | 27,307,000 |
Investments | 179,000 | |
Fair Value, Inputs, Level 2 [Member] | Convertible Securities [Member] | ||
Cash and Cash Equivalents [Line Items] | ||
Adjusted Cost | 1,023,000 | |
Unrealized Gain/(Loss) | ||
Fair Value | 39,000 | |
Cash and Cash Equivalents | ||
Current marketable securities | ||
Investments | 39,000 | |
Fair Value, Inputs, Level 2 [Member] | Warrant [Member] | ||
Cash and Cash Equivalents [Line Items] | ||
Adjusted Cost | 3,318,000 | |
Unrealized Gain/(Loss) | ||
Fair Value | 140,000 | |
Cash and Cash Equivalents | ||
Current marketable securities | ||
Investments | 140,000 | |
Cash [Member] | ||
Cash and Cash Equivalents [Line Items] | ||
Adjusted Cost | 9,971,000 | 19,226,000 |
Unrealized Gain/(Loss) | ||
Fair Value | 9,971,000 | 19,226,000 |
Cash and Cash Equivalents | 9,971,000 | 19,226,000 |
Current marketable securities | ||
Investments | ||
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Cash and Cash Equivalents [Line Items] | ||
Adjusted Cost | 62,000 | 64,000 |
Unrealized Gain/(Loss) | ||
Fair Value | 62,000 | 64,000 |
Cash and Cash Equivalents | 62,000 | 64,000 |
Current marketable securities | ||
Investments | ||
Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Cash and Cash Equivalents [Line Items] | ||
Adjusted Cost | 15,165,000 | 36,263,000 |
Unrealized Gain/(Loss) | (3,590,000) | (3,659,000) |
Fair Value | 11,575,000 | 27,307,000 |
Cash and Cash Equivalents | ||
Current marketable securities | $ 11,575,000 | 27,307,000 |
Investments |
Provision for Credit Losses (De
Provision for Credit Losses (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended |
Jun. 30, 2023 | Jun. 30, 2023 | Dec. 31, 2022 | |
Financing Receivable, Past Due [Line Items] | |||
Outstanding principal and interest | $ 9,300,000 | $ 9,300,000 | |
General Loan Portfolio Reserve [Member] | American Pacific Bancorp [Member] | |||
Financing Receivable, Past Due [Line Items] | |||
Portfolio reserve | 145,000 | $ 199,000 | |
Specific Loan Reserves [Member] | American Pacific Bancorp [Member] | Asili LLC [Member] | |||
Financing Receivable, Past Due [Line Items] | |||
Current nonaccrual loan balance | 884,000 | ||
Resvered principal amount | 27,831,000 | 27,831,000 | $ 27,831,000 |
Outstanding principal and interest | 2,884,000 | 2,884,000 | |
Loan [Member] | |||
Financing Receivable, Past Due [Line Items] | |||
Portfolio loan incurred | $ 3,757,000 | $ 3,757,000 |
Schedule of Assets and Liabilit
Schedule of Assets and Liabilities Discontinued Operations (Details) - USD ($) | Jun. 30, 2023 | Dec. 31, 2022 |
Current assets: | ||
Total current assets | $ 1,524,000 | |
Current liabilities: | ||
Total current liabilities | 1,129,000 | |
Long Term Lease liability | 59,000 | |
HWH World Inc [Member] | ||
Current assets: | ||
Cash and cash equivalents | 135,000 | |
Accounts receivable, net | 423,000 | |
Inventory | 807,000 | |
Current portion of notes receivable | 68,000 | |
Prepaid expenses and other current assets | 91,000 | |
Total current assets | 1,524,000 | |
Property, Plant & Equipment | 117,000 | |
Right of use assets | 70,000 | |
Other Intangible assets | 293,000 | |
Total assets | 2,004,000 | |
Current liabilities: | ||
Accounts payable | 978,000 | |
Accrued expenses and deferred revenue | 21,000 | |
Current Portion of Lease liability | 130,000 | |
Total current liabilities | 1,129,000 | |
Long Term Lease liability | 59,000 | |
Total liabilities | $ 1,188,000 |
Held For Sale Assets and Liab_3
Held For Sale Assets and Liabilities (Details Narrative) - USD ($) | Jul. 01, 2023 | Jun. 30, 2023 | Dec. 31, 2022 |
Common stock, par value | $ 0.02 | $ 0.02 | |
HWH World Inc [Member] | Sharing Services Global Corporation [Member] | |||
Number of shares, issued | 1,000 | ||
Common stock, par value | $ 0.01 | ||
Gross proceeds | $ 711,000 |
Investments (Details Narrative)
Investments (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||
Jul. 22, 2021 | Apr. 01, 2021 | Mar. 18, 2021 | Mar. 15, 2021 | Dec. 30, 2020 | Dec. 19, 2020 | Sep. 10, 2020 | Sep. 30, 2021 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Marketable securities | $ 148,000 | $ 148,000 | ||||||||||||||
Unrealized gain loss on investments | (3,590,000) | $ (3,659,000) | ||||||||||||||
Investments | $ 179,000 | |||||||||||||||
Issuance of common stock, net of expenses | 268,000 | $ 1,518,000 | ||||||||||||||
Proceeds from Issuance of common stock | 1,518,000 | |||||||||||||||
Vivacitas Agreement [Member] | ||||||||||||||||
Stock options exercised | 1,000,000 | |||||||||||||||
Stock options exercised | $ 1,000,000 | |||||||||||||||
Investment ownership percentage | 100% | 100% | ||||||||||||||
Investment Owned, Cost | $ 4,100,000 | |||||||||||||||
Common Stock [Member] | ||||||||||||||||
Issuance of common stock, net of expenses | $ 25,000 | $ 80,000 | ||||||||||||||
Issuance of common stock, net of expenses, shares | 1,247,000 | 3,987,000 | ||||||||||||||
BMI Capital International LLC [Member] | ||||||||||||||||
Issuance of common stock, net of expenses | $ 100,000 | |||||||||||||||
Investments equity method | $ 22,000 | $ 26,000 | ||||||||||||||
Impact Oncology PTE Ltd. [Member] | ||||||||||||||||
Owners shares | 2,480,000 | |||||||||||||||
Options to purchase additional shares | 250,000 | |||||||||||||||
Consideration transferred | $ 2,480,000 | |||||||||||||||
Stemtech Corporation [Member] | Securities Purchase Agreement [Member] | ||||||||||||||||
Investments | $ 1,400,000 | $ 1,400,000 | ||||||||||||||
Consideration transferred | 1,400,000 | |||||||||||||||
[custom:ConvertiblePromissoryNote-0] | $ 1,400,000 | 1,400,000 | ||||||||||||||
[custom:OriginationFee] | $ 500,000 | |||||||||||||||
Debt Instrument, Maturity Date | Sep. 09, 2024 | |||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | 10% | ||||||||||||||
Stockholders' Equity, Other Shares | 154,173 | |||||||||||||||
Class of Warrant or Right, Outstanding | 0 | 0 | ||||||||||||||
Convertible Notes Payable | $ 39,000 | $ 44,000 | ||||||||||||||
DSS Securities, Inc. [Member] | ||||||||||||||||
Equity method investment ownership percentage | 14.90% | |||||||||||||||
BMI Capital International LLC [Member] | ||||||||||||||||
Equity method investment ownership percentage | 24.90% | |||||||||||||||
BMI Capital International LLC [Member] | Minimum [Member] | ||||||||||||||||
Equity method investment ownership percentage | 20% | |||||||||||||||
Bio Med Technologies Asia Pacific Holdings Limited [Member] | ||||||||||||||||
Equity method investment ownership percentage | 4.99% | |||||||||||||||
Issuance of common stock, net of expenses | $ 632,000 | |||||||||||||||
Issuance of common stock, net of expenses, shares | 525 | |||||||||||||||
Vivacitas Oncology Inc [Member] | Vivacitas Agreement [Member] | ||||||||||||||||
Equity method investment ownership percentage | 16% | |||||||||||||||
Moji Life LLC [Member] | Membership Unit Purchase Agreement [Member] | ||||||||||||||||
Equity method investment ownership percentage | 30.75% | 30.75% | ||||||||||||||
Payments to acquire equity method investments | $ 1,537,000 | |||||||||||||||
Alset International Limited [Member] | ||||||||||||||||
Owners shares | 127,179,291 | 127,179,291 | 127,179,291 | |||||||||||||
Outstanding share percentage | 4% | |||||||||||||||
Marketable securities | $ 1,501,000 | $ 1,501,000 | $ 3,319,000 | $ 3,319,000 | ||||||||||||
Unrealized gain loss on investments | 1,945,000 | 1,068,000 | ||||||||||||||
Alset International Limited [Member] | Executive Director And Chief Executive Officer [Member]. | ||||||||||||||||
Unrealized gain loss on investments | 1,945,000 | $ 1,068,000 | ||||||||||||||
West Park Capital Inc [Member] | ||||||||||||||||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 7.50% | |||||||||||||||
Investments | $ 500,000 | $ 500,000 | $ 500,000 | |||||||||||||
DSS Securities, Inc. [Member] | ||||||||||||||||
Issuance of common stock, net of expenses | $ 100,000 | |||||||||||||||
Outstanding membership interest | 10% | |||||||||||||||
Vivacitas Oncology Inc [Member] | ||||||||||||||||
Options to purchase additional shares | 1,500,000 | |||||||||||||||
Shares issued, price per share | $ 1 | |||||||||||||||
Additional price per share | $ 1 | |||||||||||||||
Proceeds from Issuance of common stock | $ 500,000 | |||||||||||||||
Consideration transferred | $ 120,000 | |||||||||||||||
Sale of stock, description | the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021 and March 31, 2022. | |||||||||||||||
Share Price | $ 1 | |||||||||||||||
Vivacitas Oncology Inc [Member] | Common Stock [Member] | ||||||||||||||||
Options to purchase additional shares | 500,000 |
Schedule of Business Acquisitio
Schedule of Business Acquisition, Pro Forma Information (Details) | 12 Months Ended |
Dec. 31, 2022 USD ($) $ / shares | |
Business Combination and Asset Acquisition [Abstract] | |
Revenue | $ | $ 49,076,804 |
Net loss | $ | $ (61,680,088) |
Basic loss per share | $ / shares | $ (0.55) |
Diluted loss per share | $ / shares | $ (0.55) |
Acquisitions (Details Narrative
Acquisitions (Details Narrative) - USD ($) | Sep. 30, 2021 | May 13, 2021 | Jun. 30, 2023 | Dec. 31, 2022 |
Business Acquisition [Line Items] | ||||
Investments | $ 179,000 | |||
Goodwill | $ 57,880,000 | 60,919,000 | ||
Sentinel Brokers Company Inc [Member] | ||||
Business Acquisition [Line Items] | ||||
Purchae price | $ 300,000 | |||
Contribution of capital | $ 750,000 | |||
Investments | $ 1,050,000 | |||
Sentinel Brokers Company Inc [Member] | Common Class A [Member] | ||||
Business Acquisition [Line Items] | ||||
Percentage of outstanding common stock | 50.10% | |||
American Pacific Bancorp [Member] | ||||
Business Acquisition [Line Items] | ||||
Assets acquisition for cash | 3,977,000 | |||
Assets receivables | 344,000 | |||
Fixed assets | 1,000 | |||
Goodwill | $ 1,274,000 | |||
Sentinel Brokers Company Inc [Member] | ||||
Business Acquisition [Line Items] | ||||
Ownership percent | 24.90% | 75% |
Schedule of Notes Payable and L
Schedule of Notes Payable and Long-term Debt (Details) | Jun. 30, 2023 USD ($) |
Debt Disclosure [Abstract] | |
2023 | $ 47,206,000 |
2024 | 3,801,000 |
2025 | 858,000 |
2026 | 901,000 |
2027 | 947,000 |
Thereafter | $ 711,000 |
Short-Term and Long-Term Debt_2
Short-Term and Long-Term Debt (Details Narrative) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||||||
May 17, 2022 USD ($) shares | Mar. 17, 2022 USD ($) | Nov. 02, 2021 USD ($) | Oct. 13, 2021 USD ($) | Aug. 01, 2021 USD ($) ft² | Mar. 16, 2021 USD ($) | Nov. 30, 2021 USD ($) | Jun. 30, 2023 USD ($) | Mar. 31, 2023 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2023 USD ($) | Mar. 30, 2023 USD ($) | Dec. 31, 2021 USD ($) | May 20, 2021 USD ($) | Mar. 02, 2020 USD ($) $ / shares | |
Short-Term Debt [Line Items] | ||||||||||||||||||
Long term debt current | $ 47,206,000 | $ 47,206,000 | $ 47,161,000 | |||||||||||||||
Payments to acquire assets | 496,000 | $ 976,000 | ||||||||||||||||
Interest expense | 138,000 | $ 121,000 | 388,000 | $ 1,499,000 | ||||||||||||||
BMIC Loan [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 3,000,000 | 512,000 | 512,000 | $ 3,000,000 | ||||||||||||||
Maturity date | Oct. 12, 2022 | |||||||||||||||||
Wilson Loan [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 3,000,000 | 1,997,000 | 1,997,000 | $ 3,008,000 | ||||||||||||||
Maturity date | Oct. 12, 2022 | |||||||||||||||||
Security Agreement [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | 773,000 | 773,000 | $ 790,000 | |||||||||||||||
Principal interest percentage | 7.44% | |||||||||||||||||
Long term debt | 663,000 | 663,000 | ||||||||||||||||
Long term debt current | 110,000 | 110,000 | ||||||||||||||||
Interest Expense, Debt | 14,000 | |||||||||||||||||
American Medical REIT Inc. [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 8,350,000 | |||||||||||||||||
Principal interest percentage | 1% | |||||||||||||||||
Proceeds from Paycheck Protection Program | $ 110,000 | |||||||||||||||||
Long term debt | $ 111,000 | |||||||||||||||||
Premier Packaging Bank Of America NA [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | 3,172,000 | $ 3,406,000 | 3,172,000 | |||||||||||||||
Principal interest percentage | 4.63% | |||||||||||||||||
Long term debt | 2,687,000 | 2,687,000 | ||||||||||||||||
Debt Financing Amount | $ 3,710,000 | |||||||||||||||||
Long term debt current | 485,000 | 485,000 | ||||||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 6,155,000 | |||||||||||||||||
Principal interest percentage | 4.25% | |||||||||||||||||
Long term debt | 4,590,000 | 4,590,000 | ||||||||||||||||
Long term debt current | $ 5,105,000 | 168,000 | 168,000 | |||||||||||||||
Debt instrument description | The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5 year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months | |||||||||||||||||
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid | $ 2,829,000 | |||||||||||||||||
Debt effective interest rate percentage | 4.25% | |||||||||||||||||
Area of Land | ft² | 40,000 | |||||||||||||||||
Payments to acquire assets | 4,696,000 | |||||||||||||||||
Payments to intangible assets | $ 585,000 | |||||||||||||||||
Debt issuance costs | 61,000 | 61,000 | ||||||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Facility [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | 4,640,000 | |||||||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Land [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | 1,600,000 | |||||||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Tenant Improvements [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | $ 325,000 | |||||||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Other Intangible Assets [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Estimated useful life | 3 years | |||||||||||||||||
Pinnacle Bank [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | 40,200,000 | 40,200,000 | ||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 40,300,000 | 40,380,000 | $ 40,193,000 | 40,380,000 | ||||||||||||||
Debt instrument description | The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28%, with the first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in full | |||||||||||||||||
Debt effective interest rate percentage | 8.46% | |||||||||||||||||
Payments to acquire assets | $ 52,407,000 | |||||||||||||||||
Payments to intangible assets | $ 15,901,000 | |||||||||||||||||
Debt issuance costs | 106,000 | $ 270,000 | 106,000 | |||||||||||||||
Maturity date | Nov. 02, 2023 | |||||||||||||||||
Purchase price | $ 62,000,000 | |||||||||||||||||
Interest expense | 2,418,000 | 297,000 | ||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Extended Maturity [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Maturity date | Nov. 02, 2024 | |||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Minimum [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Estimated useful life | 1 year | |||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Maximum [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Estimated useful life | 11 years | |||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Facility [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | $ 32,100,000 | |||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Land [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | 12,100,000 | |||||||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Site Improvements [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | $ 1,500,000 | |||||||||||||||||
Unsecured Promissory Note [Member] | American Medical REIT Inc. [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 200,000 | |||||||||||||||||
Principal interest percentage | 8% | |||||||||||||||||
Class of warrant exercise price per share | $ / shares | $ 5 | |||||||||||||||||
Warrants and rights outstanding | $ 200,000 | |||||||||||||||||
Alset Note [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 8,350,000 | $ 8,350,000 | 8,350,000 | 8,805,000 | ||||||||||||||
Principal interest percentage | 8% | |||||||||||||||||
Long term debt | 8,805,000 | |||||||||||||||||
Interest expense | 346,000 | 455,000 | ||||||||||||||||
Debt instrument, maturity date description | matures in December 2023 | |||||||||||||||||
Shares issued for convertible debt | shares | 21,366,177 | |||||||||||||||||
Accrued unpaid interest | $ 119,000 | 119,000 | ||||||||||||||||
Pinnacle Loan [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Debt instrument, face amount | $ 2,990,000 | 52,000 | 52,000 | |||||||||||||||
Principal interest percentage | 4.28% | |||||||||||||||||
Payments to acquire assets | $ 4,450,000 | |||||||||||||||||
Payments to intangible assets | $ 29,000 | |||||||||||||||||
Estimated useful life | 5 years | |||||||||||||||||
Debt issuance costs | $ 2,951,000 | 2,951,000 | ||||||||||||||||
Maturity date | Mar. 07, 2024 | |||||||||||||||||
Purchase price | $ 4,500,000 | |||||||||||||||||
Interest expense | $ 153,000 | $ 24,000 | ||||||||||||||||
Debt instrument term | 25 years | |||||||||||||||||
Pinnacle Loan [Member] | Facility [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | $ 3,200,000 | |||||||||||||||||
Pinnacle Loan [Member] | Land [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | 1,000,000 | |||||||||||||||||
Pinnacle Loan [Member] | Site and Tenant Improvements [Member] | ||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||
Payments to acquire assets | $ 222,000 |
Schedule of Future Minimum Leas
Schedule of Future Minimum Lease Payments (Details) - USD ($) | Jun. 30, 2023 | Dec. 31, 2022 |
Lease Liability | ||
2023 | $ 633,000 | |
2025 | 803,000 | |
2026 | 794,000 | |
2027 | 808,000 | |
2028 | 824,000 | |
After | 4,675,000 | |
Total lease payments | 9,487,000 | |
Less: Imputed Interest | (1,734,000) | |
Present value of remaining lease payments | 7,753,000 | |
Current | 633,000 | $ 796,000 |
Noncurrent | $ 7,120,000 | $ 7,820,000 |
Weighted-average remaining lease term (years) | 13 years 10 months 24 days | |
Weighted-average discount rate | 4.30% |
Lease Liability (Details Narrat
Lease Liability (Details Narrative) | 1 Months Ended |
Mar. 31, 2022 USD ($) | |
Minimum [Member] | |
Operating lease payment | $ 61,000 |
Maximum [Member] | |
Operating lease payment | $ 78,000 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) - License Agreement [Member] - Bio Medical [Member] | Mar. 19, 2022 USD ($) |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
Loss contingency allegations | In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $1,250,000. As of June 30, 2023 and December 31, 2022, no liability has been recorded in relation to the Equivir License as development of the Equivir technology has not begun and no reasonable amount can be estimated |
Research and development expense | $ 1,250,000 |
Stockholders_ Equity (Details N
Stockholders’ Equity (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | ||||||||
May 25, 2022 | May 17, 2022 | May 05, 2022 | Mar. 10, 2022 | Mar. 09, 2022 | Feb. 28, 2022 | Jun. 30, 2023 | Jun. 30, 2023 | Jun. 30, 2022 | Feb. 18, 2022 | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||
Number of shares of common stock, value | $ 268,000 | $ 1,518,000 | ||||||||
Shares issued for convertible debt, value | ||||||||||
Stock Issued During Period, Shares, Acquisitions | 17,570,948 | |||||||||
Number of option forfeited | 2,000 | |||||||||
True Partners Capital Holdings Limited [Member] | ||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||
Stock Issued During Period, Shares, Acquisitions | 62,122,908 | |||||||||
Share Price | $ 0.41 | |||||||||
Alset EHome International, Inc. [Member] | ||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||
Shares issued for convertible debt | 21,366,177 | |||||||||
Shares issued for convertible debt, value | $ 8,350,000 | |||||||||
Accrued unpaid interest | $ 367,000 | |||||||||
Stock Purchase Agreement [Member] | ||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||
Number of shares of common stock | 3,986,877 | 44,619,423 | ||||||||
Issued price per share | $ 0.3810 | |||||||||
Number of shares of common stock, value | $ 1,519,000 | $ 17,000,000 | ||||||||
Stock Purchase Agreement [Member] | Alset EHome International, Inc. [Member] | ||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||
Number of shares of common stock | 3,986,877 | 44,619,423 | ||||||||
Issued price per share | $ 0.3810 | |||||||||
Number of shares of common stock, value | $ 1,519,000 | $ 17,000,000 | ||||||||
Employment Agreement [Member] | Heng Fai Ambrose Chan [Member] | ||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||
Number of shares of common stock | 15,389,995 | 894,084 | ||||||||
Number of shares of common stock, value | $ 5,848,000 | $ 340,000 | ||||||||
Employment Agreement [Member] | Frank Heuszel [Member] | ||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||
Number of shares of common stock | 63,205 | |||||||||
Number of shares of common stock, value | $ 29,000 |
Schedule of Supplemental Cash F
Schedule of Supplemental Cash Flow Information (Details) - USD ($) | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Supplemental Cash Flow Elements [Abstract] | ||
Cash paid for interest | $ 1,402,000 | $ 1,499,000 |
Schedule of Operations by Repor
Schedule of Operations by Reportable Segment (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Segment Reporting Information [Line Items] | ||||
Revenue | $ 7,233,000 | $ 11,771,000 | $ 19,064,000 | $ 24,064,000 |
Interest expense | 138,000 | 388,000 | ||
interest Income | 407,000 | 139,000 | 538,000 | 295,000 |
Net income (loss) from continuing operations | (37,723,000) | (5,410,000) | (46,357,000) | (14,361,000) |
Capital expenditures | 19,000 | 269,000 | 613,000 | 976,000 |
Identifiable assets | 202,744,000 | 282,948,000 | 202,744,000 | 282,948,000 |
Assets held for sale | 2,004,000 | 2,004,000 | ||
Interest expense | 138,000 | 121,000 | 388,000 | 1,499,000 |
Interest income | 538,000 | |||
Stock based compensation | 4,000 | |||
Operating Segments [Member] | Product Packaging [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 3,626,000 | 3,599,000 | 9,661,000 | 7,168,000 |
Interest expense | 47,000 | 86,000 | ||
interest Income | 1,000 | |||
Net income (loss) from continuing operations | (205,000) | 365,000 | 491,000 | 323,000 |
Capital expenditures | 4,000 | 254,000 | 580,000 | 943,000 |
Identifiable assets | 23,080,000 | 26,688,000 | 23,080,000 | 26,688,000 |
Assets held for sale | ||||
Interest expense | 34,000 | 58,000 | ||
Interest income | ||||
Stock based compensation | 1,000 | |||
Operating Segments [Member] | Commercial Banking [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 197,000 | 831,000 | 314,000 | 960,000 |
Interest expense | ||||
interest Income | ||||
Net income (loss) from continuing operations | (1,213,000) | 25,000 | (1,777,000) | 207,000 |
Capital expenditures | ||||
Identifiable assets | 41,324,000 | 52,416,000 | 41,324,000 | 52,416,000 |
Assets held for sale | ||||
Interest expense | ||||
Interest income | ||||
Stock based compensation | ||||
Operating Segments [Member] | Direct Marketing Online Sales [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 1,572,000 | 6,111,000 | 5,566,000 | 13,043,000 |
Interest expense | ||||
interest Income | 280,000 | 2,000 | ||
Net income (loss) from continuing operations | (28,074,000) | 892,000 | (31,260,000) | (3,472,000) |
Capital expenditures | (4,000) | 12,000 | 14,000 | |
Identifiable assets | 7,159,000 | 52,267,000 | 7,159,000 | 52,267,000 |
Assets held for sale | 2,004,000 | 2,004,000 | ||
Interest expense | (321,000) | |||
Interest income | 285,000 | |||
Stock based compensation | ||||
Operating Segments [Member] | Biotechnology [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 94,000 | 94,000 | ||
Interest expense | ||||
interest Income | 49,000 | 91,000 | ||
Net income (loss) from continuing operations | (3,934,000) | (673,000) | (4,782,000) | (1,289,000) |
Capital expenditures | 12,000 | 17,000 | ||
Identifiable assets | 49,952,000 | 56,524,000 | 49,952,000 | 56,524,000 |
Assets held for sale | ||||
Interest expense | ||||
Interest income | 143,000 | |||
Stock based compensation | ||||
Operating Segments [Member] | Securities [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 1,838,000 | 823,000 | 3,523,000 | 2,497,000 |
Interest expense | 91,000 | 302,000 | ||
interest Income | 78,000 | 34,000 | ||
Net income (loss) from continuing operations | (4,413,000) | (3,332,000) | (6,441,000) | (5,838,000) |
Capital expenditures | 7,000 | 2,000 | 35,000 | 15,000 |
Identifiable assets | 71,610,000 | 85,436,000 | 71,610,000 | 85,436,000 |
Assets held for sale | ||||
Interest expense | 408,000 | 1,441,000 | ||
Interest income | 110,000 | |||
Stock based compensation | ||||
Operating Segments [Member] | Corporate Segment [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 313,000 | 302,000 | ||
Interest expense | ||||
interest Income | 11,000 | |||
Net income (loss) from continuing operations | 116,000 | (2,687,000) | (2,588,000) | (4,292,000) |
Capital expenditures | 1,000 | (19,000) | 4,000 | |
Identifiable assets | 9,619,000 | 9,617,000 | 9,619,000 | 9,617,000 |
Assets held for sale | ||||
Interest expense | ||||
Interest income | ||||
Stock based compensation | $ 3,000 |
Schedule of Disaggregation of R
Schedule of Disaggregation of Revenue (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Segment Reporting Information [Line Items] | ||||
Total Printed Products | $ 3,626,000 | $ 4,048,000 | $ 9,661,000 | $ 7,617,000 |
Direct Marketing | 1,572,000 | 6,070,000 | 5,566,000 | 13,002,000 |
Total Rental Income | 1,543,000 | 1,508,000 | 3,228,000 | 3,171,000 |
Total Net Investment Income | 197,000 | 145,000 | 314,000 | 274,000 |
Total Commission income | 295,000 | 295,000 | ||
Packaging Printing and Fabrication [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total Printed Products | 3,571,000 | 3,952,000 | 9,341,000 | 7,468,000 |
Commercial and Security Printing [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total Printed Products | 55,000 | 96,000 | 320,000 | 149,000 |
Direct Marketing Internet Sales [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Direct Marketing | 1,572,000 | 6,070,000 | 5,566,000 | 13,002,000 |
Rental Income [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total Rental Income | 1,543,000 | 1,508,000 | 3,228,000 | 3,171,000 |
Net Investment Income [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total Net Investment Income | 197,000 | 145,000 | 314,000 | 274,000 |
Commission Income [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Total Commission income | $ 295,000 | $ 295,000 |
Segment Information (Details Na
Segment Information (Details Narrative) | 6 Months Ended |
Jun. 30, 2023 Segments | |
Segment Reporting [Abstract] | |
Number of operating segments | 5 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | 1 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||||||
Aug. 09, 2022 | May 17, 2022 | Mar. 09, 2022 | Feb. 28, 2022 | Oct. 13, 2021 | Mar. 18, 2021 | Oct. 31, 2017 | Nov. 30, 2021 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2023 | Mar. 31, 2023 | Jul. 01, 2022 | Feb. 18, 2022 | Mar. 16, 2021 | Mar. 02, 2020 | |
Marketable securities | $ 148,000 | ||||||||||||||||
Unrealized loss on investment | (3,590,000) | $ (3,659,000) | |||||||||||||||
Purchase price | 268,000 | $ 1,518,000 | |||||||||||||||
Number of shares issued for acquisition | 17,570,948 | ||||||||||||||||
BMIC Loan [Member] | |||||||||||||||||
Debt instrument, face amount | $ 3,000,000 | 512,000 | 3,000,000 | ||||||||||||||
Debt instrument maturity date | Oct. 12, 2022 | ||||||||||||||||
Wilson Loan [Member] | |||||||||||||||||
Debt instrument, face amount | $ 3,000,000 | $ 1,997,000 | $ 3,008,000 | ||||||||||||||
Debt instrument maturity date | Oct. 12, 2022 | ||||||||||||||||
Stock Purchase Agreement [Member] | |||||||||||||||||
Number of shares of common stock | 3,986,877 | 44,619,423 | |||||||||||||||
Issued price per share | $ 0.3810 | ||||||||||||||||
Purchase price | $ 1,519,000 | $ 17,000,000 | |||||||||||||||
Impact Oncology PTE Ltd. [Member] | |||||||||||||||||
Investment owned balance shares | 2,480,000 | ||||||||||||||||
Consideration transferred | $ 2,480,000 | ||||||||||||||||
Options to purchase additional shares | 250,000 | ||||||||||||||||
True Partners Capital Holdings Limited [Member] | |||||||||||||||||
Number of shares issued for acquisition | 62,122,908 | ||||||||||||||||
Share price | $ 0.41 | ||||||||||||||||
Alset Note [Member] | |||||||||||||||||
Debt instrument, face amount | $ 8,350,000 | $ 8,350,000 | $ 8,805,000 | $ 8,350,000 | |||||||||||||
Prime plus rate percentage | 8% | ||||||||||||||||
Debt instrument maturity date, description | matures in December 2023 | ||||||||||||||||
Shares issued for convertible debt | 21,366,177 | ||||||||||||||||
Accrued unpaid interest | $ 119,000 | 119,000 | |||||||||||||||
Alset International Limited [Member] | |||||||||||||||||
Investment owned balance shares | 127,179,291 | 127,179,291 | |||||||||||||||
Warrants percentage | 4% | ||||||||||||||||
Marketable securities | $ 1,501,000 | $ 3,319,000 | $ 3,319,000 | ||||||||||||||
Unrealized loss on investment | $ 1,945,000 | $ 1,068,000 | |||||||||||||||
Shares issued for convertible debt | 21,366,177 | ||||||||||||||||
American Medical REIT Inc. [Member] | |||||||||||||||||
Debt instrument, face amount | $ 8,350,000 | ||||||||||||||||
Prime plus rate percentage | 1% | ||||||||||||||||
Unpaid interest | $ 367,000 | ||||||||||||||||
American Medical REIT Inc. [Member] | Unsecured Promissory Note [Member] | |||||||||||||||||
Debt instrument, face amount | $ 200,000 | ||||||||||||||||
Prime plus rate percentage | 8% | ||||||||||||||||
Exercise price of warrants | $ 5 | ||||||||||||||||
Warrants and rights outstanding | $ 200,000 | ||||||||||||||||
HWH International Inc [Member] | |||||||||||||||||
Debt instrument, face amount | $ 50,000 | ||||||||||||||||
Issued price per share | $ 0.15 | ||||||||||||||||
Conversion of stock | 333,333 | ||||||||||||||||
Warrants to purchase | 333,333 | ||||||||||||||||
Cancelleation of warrants and notes | $ 78,635.62 | ||||||||||||||||
Alset EHome [Member] | |||||||||||||||||
Share price | $ 0.34 |